Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 29.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 137,284 shares of the company’s stock after purchasing an additional 31,298 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Moderna were worth $23,649,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in the stock. Virginia Retirement Systems ET AL boosted its position in Moderna by 111.3% during the 1st quarter. Virginia Retirement Systems ET AL now owns 61,700 shares of the company’s stock worth $10,628,000 after buying an additional 32,500 shares during the period. CWM LLC boosted its position in Moderna by 112.7% during the 1st quarter. CWM LLC now owns 6,784 shares of the company’s stock worth $1,169,000 after buying an additional 3,595 shares during the period. Lindbrook Capital LLC boosted its position in Moderna by 7.0% during the 1st quarter. Lindbrook Capital LLC now owns 2,262 shares of the company’s stock worth $390,000 after buying an additional 148 shares during the period. Riverview Trust Co acquired a new stake in Moderna during the 1st quarter worth approximately $40,000. Finally, Prairiewood Capital LLC acquired a new stake in Moderna during the 1st quarter worth approximately $724,000. 61.20% of the stock is currently owned by institutional investors.
Several equities research analysts recently commented on the stock. SVB Leerink cut their target price on shares of Moderna from $80.00 to $70.00 and set an “underperform” rating on the stock in a research report on Tuesday, June 7th. Piper Sandler cut their target price on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 17th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Moderna from $175.00 to $155.00 and set a “hold” rating on the stock in a research report on Monday, March 7th. Finally, Morgan Stanley boosted their price target on shares of Moderna from $205.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $228.00.
Moderna (NASDAQ:MRNA – Get Rating) last released its earnings results on Wednesday, May 4th. The company reported $8.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.18 by $3.40. Moderna had a net margin of 64.77% and a return on equity of 121.86%. The company had revenue of $6.07 billion for the quarter, compared to the consensus estimate of $4.43 billion. During the same quarter in the previous year, the company earned $2.84 EPS. Moderna’s quarterly revenue was up 213.2% compared to the same quarter last year. Sell-side analysts expect that Moderna, Inc. will post 27.27 EPS for the current fiscal year.
In other Moderna news, CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction on Wednesday, April 6th. The shares were sold at an average price of $158.70, for a total transaction of $1,428,300.00. Following the completion of the sale, the chief executive officer now owns 5,456,535 shares in the company, valued at approximately $865,952,104.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 20,000 shares of the business’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $177.27, for a total transaction of $3,545,400.00. Following the sale, the president now owns 1,622,532 shares of the company’s stock, valued at approximately $287,626,247.64. The disclosure for this sale can be found here. Insiders have sold a total of 426,029 shares of company stock worth $60,093,195 in the last quarter. 17.30% of the stock is owned by corporate insiders.
Moderna Company Profile (Get Rating)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
- RH Gives Good Reason To Get Defensive
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.